201 Therapeutics, which stems from the University of Basel, is researching liver cancer drugs using organoids derived from patient tumours. The CHF 150,000 InnoBooster from Gebert Rüf Stiftung funds in vivo validation of its most advanced molecule series.
- Announced on
- Round
- Grant
- Amount
- CHF 150,000
- Sector
- Biotech & life sciences
Investors
- Gebert Rüf Stiftung lead
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic